Today, the market overall showed a narrow range of fluctuations in trends. The trends of the three major indexes were differentiated, the Shanghai Composite Index fell slightly, and the ChiNext Index rose slightly. Pharmaceutical stocks were strong throughout the day, while traditional Chinese medicine stocks led the rise. The logistics sector strengthened, track stocks rebounded, and the energy storage direction led the rise. Agricultural stocks fell into adjustment
Overall, stocks fell more and rose less, and more than 2,500 stocks in the two markets fell. The turnover of is 4793.8 billion, a decrease of 13.5 billion from the previous trading day. As of the close, the Shanghai Composite Index fell 0.13%, the Shenzhen Component Index rose 0.23%, and the ChiNext Index rose 0.49%. Northbound funds sold a net sale of 3.757 billion yuan throughout the day
1. Today, the market has generally maintained a short-term narrow digestion trend. Some of the strong stocks recently also have a short-term digestion process. Today is not technically the focus. I said in the morning that even if the fluctuations throughout the day are a reasonable process, the technical details have been grasped and analyzed. The struggle between long and short in the second half of the week will begin to intensify. Today is only a brief digestion of the market. We can wait and see the game in the second half of the week. This is not something we can control, because there are no cyclical effectiveness factors here.
2. Today, the pharmaceutical industry chain has strengthened comprehensively. You can see that Chinese medicine, new crown treatment, pharmaceutical business and other sectors all have growth rates.
Among them, GEM Weikang Pharmaceutical won 20CM daily limit, Nocheng Jianhua , Shanghai Yizhong, BeiGene rose by more than 10%, Huasen Pharmaceutical , China Resources Sanjiu, Essence Pharmaceutical , Panlong Pharmaceutical, Weixinkang, Cube Pharmaceutical and other stocks rose by more than 10%.
Previously, the focus of the hype of the big pharmaceutical sector was more on the new infrastructure direction (device equipment, etc.), and today the funds returned to the pharmaceutical itself.
Because the pharmaceutical industry chain has a large sector capacity, in the context of the overall sector coming to the oversold range, there are many sub-sectors waiting for funds to explore, so the direction of large pharmaceuticals is expected to form a benign rotation within the sector in the future.
The current valuation of the pharmaceutical sector is still the lowest in the past decade, and the proportion of institutional allocation is also at a low level.
Recently, domestic policies have frequently appeared, such as the 22 provincial volume-based procurement plan for liver function biochemical detection reagents, which has slowed down significantly; new indications for drugs can be renewed simply without renegotiation; and the National Health Insurance Administration once again made it clear that innovative medical devices will not be purchased at the moment, and at the same time, it has not yet considered including dental implants in the medical insurance payment scope.
policy marginal improvements are significant, and market sentiment is expected to continue to recover.
3. After experiencing a continuous rebound, it is still reasonable for the market to show a differentiated and consolidation trend today. Overall, both the main board and the ChiNext have not yet fallen below the 5-day line, and the rebound structure has not been damaged.
However, it is worth noting that under the influence of the trapped market, the intraday selling pressure gradually emerged. After two consecutive days of shrinking volume, if this round of rebound wants to further develop continuity, it should return to the pattern of volume-raising as soon as possible. Once the subsequent volume can continue to shrink, everyone should be mentally prepared.
(Classics will take you to see the world, illuminate the life of the stock market - everyone is welcome to follow and like)
